LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 21
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Healthcare Sector Analysis
UpdatedDec 22, 2024
DataAggregated Company Financials
Companies360
- 7D-4.0%
- 3M-11.3%
- 1Y12.1%
- YTD1.1%
Over the last 7 days, the Healthcare industry has dropped 4.0%, driven by a pullback from Samsung BiologicsLtd of 4.8%. In contrast, Sam Chun Dang Pharm has gained 16%. Over the past 12 months, the industry was up 12%. Looking forward, earnings are forecast to grow by 48% annually.
Sector Valuation and Performance
Has the South Korean Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Dec 2024 | ₩249.4t | ₩54.4t | ₩802.1b | 13.9x | 310.9x | 4.6x |
| Tue, 19 Nov 2024 | ₩252.2t | ₩53.2t | ₩910.6b | 14.9x | 276.9x | 4.7x |
| Thu, 17 Oct 2024 | ₩283.0t | ₩53.3t | ₩854.8b | 17.2x | 331.1x | 5.3x |
| Sat, 14 Sep 2024 | ₩264.8t | ₩53.4t | ₩856.4b | 17.3x | 309.2x | 5x |
| Mon, 12 Aug 2024 | ₩259.5t | ₩52.3t | ₩756.6b | 16.3x | 343x | 5x |
| Wed, 10 Jul 2024 | ₩244.2t | ₩52.3t | ₩749.4b | 16.3x | 325.8x | 4.7x |
| Fri, 07 Jun 2024 | ₩229.3t | ₩52.9t | ₩737.2b | 16.3x | 311.1x | 4.3x |
| Sun, 05 May 2024 | ₩234.9t | ₩52.3t | ₩545.6b | 18.4x | 430.6x | 4.5x |
| Tue, 02 Apr 2024 | ₩245.0t | ₩52.3t | ₩486.3b | 18.4x | 503.9x | 4.7x |
| Thu, 29 Feb 2024 | ₩230.9t | ₩52.0t | -₩48,458,490,006.00 | 21.7x | -4763.9x | 4.4x |
| Sat, 27 Jan 2024 | ₩234.7t | ₩55.7t | ₩55.5b | 22.9x | 4232.6x | 4.2x |
| Mon, 25 Dec 2023 | ₩221.8t | ₩56.1t | ₩267.5b | 21.7x | 829.1x | 4x |
| Wed, 22 Nov 2023 | ₩211.2t | ₩55.9t | ₩378.5b | 20.3x | 558.2x | 3.8x |
| Fri, 20 Oct 2023 | ₩193.8t | ₩56.0t | ₩1.0t | 17.5x | 189.3x | 3.5x |
| Sun, 17 Sep 2023 | ₩216.9t | ₩56.0t | ₩933.2b | 20.5x | 232.4x | 3.9x |
| Tue, 15 Aug 2023 | ₩221.6t | ₩56.1t | ₩2.1t | 23x | 106x | 3.9x |
| Thu, 13 Jul 2023 | ₩202.5t | ₩56.1t | ₩2.1t | 20.8x | 96.2x | 3.6x |
| Sat, 10 Jun 2023 | ₩217.9t | ₩56.3t | ₩2.1t | 22.1x | 103.3x | 3.9x |
| Mon, 08 May 2023 | ₩216.9t | ₩58.4t | ₩3.2t | 21.6x | 66.7x | 3.7x |
| Wed, 05 Apr 2023 | ₩209.6t | ₩58.3t | ₩3.2t | 20.1x | 64.5x | 3.6x |
| Fri, 03 Mar 2023 | ₩199.0t | ₩57.8t | ₩4.6t | 18.8x | 43.2x | 3.4x |
| Sun, 29 Jan 2023 | ₩207.7t | ₩57.8t | ₩4.6t | 16.8x | 45.1x | 3.6x |
| Tue, 27 Dec 2022 | ₩206.8t | ₩57.5t | ₩3.9t | 16x | 53.1x | 3.6x |
| Thu, 24 Nov 2022 | ₩211.3t | ₩57.0t | ₩4.0t | 16x | 52.5x | 3.7x |
| Sat, 22 Oct 2022 | ₩194.5t | ₩55.7t | ₩4.1t | 14.7x | 47.7x | 3.5x |
| Mon, 19 Sep 2022 | ₩205.4t | ₩54.8t | ₩3.8t | 17.8x | 54.3x | 3.7x |
| Wed, 17 Aug 2022 | ₩236.0t | ₩54.2t | ₩3.9t | 21.2x | 60.8x | 4.4x |
| Fri, 15 Jul 2022 | ₩224.9t | ₩54.2t | ₩3.9t | 19.4x | 57.9x | 4.2x |
| Sun, 12 Jun 2022 | ₩220.4t | ₩54.2t | ₩3.9t | 21.9x | 56.4x | 4.1x |
| Tue, 10 May 2022 | ₩218.2t | ₩51.1t | ₩3.9t | 21.1x | 56.2x | 4.3x |
| Thu, 07 Apr 2022 | ₩231.0t | ₩51.0t | ₩4.0t | 23x | 57.7x | 4.5x |
| Sat, 05 Mar 2022 | ₩225.7t | ₩49.2t | ₩4.2t | 21.9x | 53.4x | 4.6x |
| Mon, 31 Jan 2022 | ₩216.9t | ₩49.0t | ₩4.3t | 20.4x | 50.2x | 4.4x |
| Wed, 29 Dec 2021 | ₩262.2t | ₩49.0t | ₩4.3t | 24.1x | 60.7x | 5.4x |
Price to Earnings Ratio
60.7x
Current Industry PE
- Investors are optimistic on the South Korean Healthcare industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 311x which is higher than its 3-year average PE of 222x.
- The 3-year average PS ratio of 4.2x is lower than the industry's current PS ratio of 4.6x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 43% per year over the last three years.
- Meanwhile revenues for these companies have grown 3.5% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare sector?
| KR Market | -3.69% | |
| Healthcare | -4.02% | |
| Pharma | -1.75% | |
| Medical Equipment | -3.16% | |
| Biotech | -3.86% | |
| Healthcare Services | -4.80% | |
| Life Sciences | -5.56% | |
| Healthtech | -13.54% | |
Industry PE
- Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 114x.
- Analysts are expecting annual earnings growth of 19.2%, which is lower than the prior year's growth of 39.6% per year.
Forecasted Growth
- Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 82% over the next 5 years.
- This is better than its past earnings growth rate of 7.9% per year.
- In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A000250 Sam Chun Dang Pharm | ₩118.10k | 15.8% +₩374.4b | 66.8% | PE537.5x | |
| A214370 Caregen | ₩26.95k | 10.9% +₩129.8b | 0% | PE36.9x | |
| A214450 PharmaResearch | ₩253.50k | 3.5% +₩88.3b | 130.5% | PE29.7x | |
| A000640 Dong-A Socio Holdings | ₩113.20k | 12.9% +₩80.6b | 13.2% | PE12.8x | |
| A214150 CLASSYS | ₩48.75k | 2.4% +₩75.3b | 30.3% | PE37.6x |
